Featuring perspectives from Dr Sara M Tolaney, including the following topics:

• Management of adverse events associated with TROP2-targeting antibody-drug conjugates (0:00)
• Managing brain metastases in triple-negative breast cancer (6:30)
• EGFR x HER3-directed bispecific antibodies for metastatic triple-negative breast cancer (mTNBC) (9:11)
• PD-1/PD-L1 x VEGF-directed bispecific antibodies for mTNBC (12:31)

CME information and select publications

Featuring perspectives from Dr Sara M Tolaney, including the following topics:

• Mechanistic effects and potential resistance mechanisms of antibody-drug conjugates (0:00)
• First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients eligible for immunotherapy (7:13)
• First-line treatment of mTNBC in patients ineligible for immunotherapy (13:02)
• Antibody-drug conjugates for previously treated HER2-low metastatic breast cancer (19:15)

CME information and select publications

Featuring perspectives from Dr David W Cescon, including the following topics:

• Clinical treatment of BRCA-mutated metastatic triple-negative breast cancer (0:00)
• CNS activity of TROP2-directed antibody-drug conjugates (5:36)
• Autoimmune considerations with immunotherapy (10:09)
• Treatment of oligoprogressive advanced breast cancer (17:31)

CME information and select publications

Featuring perspectives from Dr David W Cescon, including the following topics:

• First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients not eligible for immunotherapy (0:00)
• First-line treatment of mTNBC in patients eligible for immunotherapy (12:05)
• Adverse events (19:39)

CME information and select publications

Featuring perspectives from Dr Aditya Bardia, Dr Kevin Kalinsky and Dr Joyce O'Shaughnessy, including the following topics:

• Introduction (0:00)
• Hormone Receptor-Positive Breast Cancer — Dr Kalinsky (1:18)
• HER2-Positive Breast Cancer — Dr Bardia (42:46)
• Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:01:41)

CME information and select publications

Featuring perspectives from Dr Lisa A Carey and Dr Maha Hussain, including the following topics:

• Introduction (0:00)
• HER2 History (1:32)
• Cases from the GMO Survey (7:06)
• Biology and Selection of First-Line Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer (mBC) — Dr Mahtani (19:56)
• Faculty Case Presentations (31:37)
• Patterns of Care Survey — Part 1 (38:26)
• Optimizing the Use of Up-Front Maintenance Therapy for HER2-Positive mBC — Dr Carey (44:53)
• Faculty Case Presentations (54:13)

CME information and select publications

Featuring perspectives from Prof Peter Schmid and Dr Melinda Telli, including the following topics:

• Introduction: TROP2-Targeting Antibody-Drug Conjugates (ADCs) for Metastatic Triple-Negative Breast Cancer (0:00)
• First-Line Therapy (PD-L1 Negative) (6:53)
• First-Line Therapy (PD-L1 Positive) (23:40)
• Second-Line Therapy (Sequencing) (34:08)
• Adverse Events with TROP2-Targeting ADCs (43:43)

CME information and select publications

Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics:

• Introduction (0:00)
• Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37)
• Practical Considerations with Oral SERDs (15:42)
• Potential Role of Combination Approaches with Oral SERDs (26:31)
• Gastrointestinal Adverse Events Documented with Oral SERDs (38:17)
• Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation (46:51)
• Other Class-Effect Toxicities Associated with Oral SERDs (1:00:53)
• Emerging Utility of Adjuvant Oral SERDs (1:10:16)
• Unique Toxicities Associated with 1 or More Oral SERDs (1:19:17)

CME information and select publications